← Back to Search

Virus Therapy

VIR-2482 (Dose 1) for Flu

Phase 2
Waitlist Available
Research Sponsored by Vir Biotechnology, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 26 weeks
Awards & highlights

Summary

This trial is testing VIR-2482, a new treatment aimed at preventing the flu (influenza A). It focuses on healthy adults aged 18 to less than 65 years who do not have risk factors for serious flu complications. The treatment likely works by boosting the immune system or directly fighting the flu virus.

Eligible Conditions
  • Flu

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 26 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 26 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Participants With Adverse Events of Special Interest (AESI)
Number of Participants With Clinical Laboratory Abnormalities
Number of Participants With Solicited Injection Site Reactions
+3 more
Secondary study objectives
Percentage of Participants With CDC-defined Influenza-like Illness (ILI) With Confirmed Influenza A (by Reverse Transcription Polymerase Chain Reaction [RT-PCR])
Percentage of Participants With WHO-defined Influenza-like Illness (ILI) With Confirmed Influenza A (by Reverse Transcription Polymerase Chain Reaction [RT-PCR])

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: VIR-2482 (Dose 2)Experimental Treatment1 Intervention
Group II: VIR-2482 (Dose 1)Experimental Treatment1 Intervention
Group III: PlaceboPlacebo Group1 Intervention

Find a Location

Who is running the clinical trial?

Vir Biotechnology, Inc.Lead Sponsor
29 Previous Clinical Trials
10,297 Total Patients Enrolled

Media Library

VIR-2482 (Virus Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05567783 — Phase 2
Flu Research Study Groups: VIR-2482 (Dose 1), Placebo, VIR-2482 (Dose 2)
Flu Clinical Trial 2023: VIR-2482 Highlights & Side Effects. Trial Name: NCT05567783 — Phase 2
VIR-2482 (Virus Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05567783 — Phase 2
~1021 spots leftby Oct 2025